glp-1 agonist weight loss medications alternatives Medications: Everything You Need to Know Emerging Weight Loss Drugs and

Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: a systematic review and meta-analysis

12 Several large, randomised trials have shown that GLP-1 RAs reduce major adverse cardiovascular events (MACE) compared with placebo

Higher TSH level is a risk factor for differentiated thyroid cancer

However, clinical trials and real-world evidence consistently show that weight reduction with GLP-1RAs is accompanied by decrease in lean body mass, raising concern in patients already predisposed to muscle wasting and underscoring the need for integrated management strategies

Blundell J, Finlayson G, Axelsen M, et al